SCHEMBL16012879

SCHEMBL16012879

CCCCCCC(CCCCCC)CCCCCC(=O)O

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 2/20 0.74
FFAR1 O14842 2/20 0.74
GPR84 Q9NQS5 7/20 0.74
PPARG P37231 7/20 0.74
PPARD Q03181 7/20 0.74
PPARA Q07869 7/20 0.74
HDAC11 Q96DB2 5/20 0.74
TSHR P16473 4/20 0.74
PTPN1 P18031 3/20 0.74
ALDH1A1 P00352 2/20 0.74
TLR2 O60603 2/20 0.74
TDP1 Q9NUW8 2/20 0.74
FABP4 P15090 2/20 0.74
KMT2A Q03164 2/20 0.74
SLC22A6 Q4U2R8 1/20 0.74
SLC22A8 Q8TCC7 1/20 0.74
MEN1 O00255 1/20 0.74
ESR1 P03372 1/20 0.74
ALOX15 P16050 1/20 0.74
PDE4A P27815 1/20 0.74

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2492074 1.00 FFAR4 (0.74) FFAR4FFAR1GPR84PPARGPPARD
Adipic Acid SCHEMBL11453017 1.00 FFAR4 (0.74) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL775625 1.00 FFAR4 (0.74) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL227364 1.00 FFAR4 (0.74) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL20943305 1.00 FFAR4 (0.74) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL25195763 1.00 FFAR4 (0.74) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL18558704 1.00 FFAR4 (0.74) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL16829864 1.00 FFAR4 (0.74) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL8421567 1.00 FFAR4 (0.74) FFAR4FFAR1GPR84PPARGPPARD
SCHEMBL10780484 1.00 FFAR4 (0.74) FFAR4FFAR1GPR84PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118317944-A Acyclic lipids and methods of use thereof 雷纳嘉德医疗管理公司 2024-07-09 CN disclosed
CN-118234707-A Cyclic lipids and methods of use thereof 雷纳嘉德医疗管理公司 2024-06-21 CN disclosed
US-20220402862-A1 IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES INTELLIA THERAPEUTICS, INC. 2022-12-22 US disclosed
US-20220402862-A1 IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES INTELLIA THERAPEUTICS, INC. 2022-12-22 US disclosed
US-11420933-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2022-08-23 US disclosed
EP-3959191-A1 IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES Intellia Therapeutics, Inc. (US) 2022-03-02 EP disclosed
CN-114127044-A Ionizable amine lipids and lipid nanoparticles 英特利亚治疗股份有限公司 2022-03-01 CN disclosed
EP-3623361-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2021-08-18 EP disclosed
EP-3608308-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2021-07-21 EP disclosed
EP-3608308-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2021-07-21 EP disclosed
US-20160311759-A1 Lipids and Lipid Compositions for the Delivery of Active Agents NOVARTIS AG (CH) 2016-10-27 US disclosed
EP-3083556-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2016-10-26 EP disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 US disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 US disclosed
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2016-04-21 US disclosed
WO-2016010840-A1 METHOD OF ENCAPSULATING A NUCLEIC ACID IN A LIPID NANOPARTICLE HOST NOVARTIS AG (CH) 2016-01-21 WO disclosed
EP-2964608-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2016-01-13 EP disclosed
WO-2015095340-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2015-06-25 WO disclosed
WO-2015095340-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2015-06-25 WO disclosed
WO-2014136086-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2014-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11420933-B2 Lipids and lipid compositions for the delivery of active agents LPAR1, LPAR4, LIPA FFAR4 208/4885FFAR1 189/4885GPR84 956/4885
US-20220402862-A1 IONIZABLE AMINE LIPIDS AND LIPID NANOPARTICLES PHOSPHO1, SGMS1, SGMS2 FFAR4 695/4885FFAR1 1223/4885GPR84 1499/4885
US-20160106842-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 FFAR4 188/4885FFAR1 193/4885GPR84 648/4885
US-20160311759-A1 Lipids and Lipid Compositions for the Delivery of Active Agents PHOSPHO1, SGMS1, ABCB4 FFAR4 165/4885FFAR1 174/4885GPR84 616/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.